These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17963115)

  • 1. Osmotic delivery of flurbiprofen through controlled porosity asymmetric membrane capsule.
    Choudhury PK; Chauhan CS; Ranawat MS
    Drug Dev Ind Pharm; 2007 Oct; 33(10):1135-41. PubMed ID: 17963115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled porosity osmotic pump for the delivery of flurbiprofen.
    Chauhan CS; Choudhury PK
    Curr Drug Deliv; 2006 Apr; 3(2):193-8. PubMed ID: 16611005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric membrane capsule for osmotic delivery of flurbiprofen.
    Choudhury PK; Ranawat MS; Pillai MK; Chauhan CS
    Acta Pharm; 2007 Sep; 57(3):343-50. PubMed ID: 17878113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects.
    Wang CY; Ho HO; Lin LH; Lin YK; Sheu MT
    Int J Pharm; 2005 Jun; 297(1-2):89-97. PubMed ID: 15885936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel design of osmotic chitosan capsules characterized by asymmetric membrane structure for in situ formation of delivery orifice.
    Wang GM; Chen CH; Ho HO; Wang SS; Sheu MT
    Int J Pharm; 2006 Aug; 319(1-2):71-81. PubMed ID: 16701971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule.
    Philip AK
    Curr Drug Deliv; 2008 Apr; 5(2):127-32. PubMed ID: 18393815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice.
    Lin YK; Ho HO
    J Control Release; 2003 Apr; 89(1):57-69. PubMed ID: 12695063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ-formed asymmetric membrane capsule for osmotic release of poorly water-soluble drug.
    Philip A; Pathak K
    PDA J Pharm Sci Technol; 2007; 61(1):24-36. PubMed ID: 17390701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled, and level A IVIVC for poorly water-soluble drug.
    Philip AK; Pathak K
    Drug Dev Ind Pharm; 2008 Jul; 34(7):735-43. PubMed ID: 18608466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system.
    Yang Y; Zhao Z; Wang Y; Yang L; Liu D; Yang X; Pan W
    Int J Pharm; 2016 Jun; 506(1-2):340-50. PubMed ID: 27132166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric membrane capsules of phenylephrine hydrochloride: an osmotically controlled drug delivery system.
    Kumar A; Philip AK; Pathak K
    Curr Drug Deliv; 2011 Sep; 8(5):474-82. PubMed ID: 21696358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel osmotic pump-based controlled delivery system consisting of pH-modulated solid dispersion for poorly soluble drug flurbiprofen: in vitro and in vivo evaluation.
    Li S; Wang X; Wang Y; Zhao Q; Zhang L; Yang X; Liu D; Pan W
    Drug Dev Ind Pharm; 2015; 41(12):2089-99. PubMed ID: 26304493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osmotically controlled oral delivery of ciprofloxacin through asymmetric membrane capsules.
    Suman M; Chauhan DK; Reddy N
    Pharmazie; 2012 Aug; 67(8):687-94. PubMed ID: 22957433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regenerated cellulose capsules for controlled drug delivery: Part IV. In-vitro evaluation of novel self-pore forming regenerated cellulose capsules.
    Bhatt B; Kumar V
    Eur J Pharm Sci; 2017 Jan; 97():227-236. PubMed ID: 27916694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiment on formulation and drug release behavior of porosity asymmetric membrane capsules in vitro.
    Fu HX; Li H; Zhang FZ; Zhao YZ; Wan CW; Chen MT; Jia XC; Yan L; Sun CC; Xu YY
    Drug Dev Ind Pharm; 2012 Jun; 38(6):670-8. PubMed ID: 22469006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of release pattern of a drug with low solubility through asymmetric membrane capsules.
    Sahoo PK; Makar H
    Indian J Pharm Sci; 2013 Mar; 75(2):205-10. PubMed ID: 24019570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Transited Asymmetric Membrane Capsule: A Means for Achieving Delayed and Controlled Osmotic Flow.
    Philip AK; Philip B
    Curr Drug Deliv; 2010 Jul; 7(3):230-7. PubMed ID: 20497101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric membrane osmotic capsules for terbutaline sulphate.
    Gobade NG; Koland M; Harish KH
    Indian J Pharm Sci; 2012 Jan; 74(1):69-72. PubMed ID: 23204625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled porosity osmotic pump system with biphasic release of theophylline.
    Bi Y; Mao S; Gan L; Li Y; Wang C; Xu N; Zheng Y; Cheng Q; Hou S
    Chem Pharm Bull (Tokyo); 2007 Nov; 55(11):1574-80. PubMed ID: 17978514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation.
    Liu H; Yang XG; Nie SF; Wei LL; Zhou LL; Liu H; Tang R; Pan WS
    Int J Pharm; 2007 Mar; 332(1-2):115-24. PubMed ID: 17052871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.